{
  "title": "Trastuzumab deruxtecan in HER2-low metastatic breast cancer: long-term survival analysis of the randomized, phase 3 DESTINY-Breast04 trialEstrogen and progesterone receptor testing in breast cancer: ASCO/CAP Guideline updateHuman epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline focused updateESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancerHuman epidermal growth factor receptor 2 testing in breast cancerRecommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline updateHER2-low breast cancer: pathological and clinical landscapeTrastuzumab deruxtecan in previously treated HER2-low advanced breast cancerAntitumor activity and safety of trastuzumab deruxtecan in patients with HER2-low-expressing advanced breast cancer: results from a phase Ib studyESMO Expert Consensus Statements (ECS) on the definition, diagnosis, and management of HER2-low breast cancerStandardized pathology report for HER2 testing in compliance with 2023 ASCO/CAP updates and 2023 ESMO consensus statements on HER2-low breast cancerClinical, pathological, and PAM50 gene expression features of HER2-low breast cancerRetrospective study to estimate the prevalence and describe the clinicopathological characteristics, treatments received, and outcomes of HER2-low breast cancerImpact of breast cancer subtypes on prognosis of women with operable invasive breast cancer: a population-based study using SEER databaseEstrogen-receptor-low-positive breast cancer: pathological and clinical perspectivesImpact of low versus negative estrogen/progesterone receptor status on clinico-pathologic characteristics and survival outcomes in HER2-negative breast cancerBorderline ER-positive primary breast cancer gains no significant survival benefit from endocrine therapy: a systematic review and meta-analysisThe significance of highlighting the oestrogen receptor low category in breast cancerOutcome of breast cancer patients with low hormone receptor positivity: analysis of a 15-year population-based cohortThe latest research and development into the antibody\u2013drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapyDS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1Assessment of predictive biomarkers in breast cancer: challenges and updatesOptimizing treatment management of trastuzumab deruxtecan in clinical practice of breast cancerMultidisciplinary clinical guidance on trastuzumab deruxtecan (T-DXd)-related interstitial lung disease/pneumonitis\u2014focus on proactive monitoring, diagnosis, and managementTrastuzumab deruxtecan in metastatic breast cancer with variable HER2 expression: the phase 2 DAISY trialTrastuzumab deruxtecan after endocrine therapy in metastatic breast cancerDetermination of HER2-low status in tumors of patients with unresectable and/or metastatic breast cancer in DESTINY-Breast04Human epidermal growth factor receptor 2 (HER2)-low and HER2-ultralow status determination in tumors of patients (pts) with hormone receptor-positive (HR+) metastatic breast cancer (mBC) in DESTINY-Breast06 (DB-06)Concordance between the DESTINY-Breast04 clinical trial assay (4B5[CDx]) and other HER2 IHC assays for HER2-low breast cancer in real-world practice: first phase of a large-scale, multicenter global ring studyExamination of low ERBB2 protein expression in breast cancer tissue",
  "pmcid": "12705423",
  "features": {
    "sample_size": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "randomization": {
      "present": true,
      "count": 2,
      "unique_matches": [
        "randomly assigned"
      ],
      "examples": [
        {
          "match": "randomly assigned",
          "context": ", per protocol. Patients were randomly assigned in a 2:1 ratio to receive T-D"
        },
        {
          "match": "randomly assigned",
          "context": "s were performed for patients randomly assigned to receive study treatment. S"
        }
      ]
    },
    "blinding": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "allocation_concealment": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "interaction_subgroup": {
      "present": true,
      "count": 6,
      "unique_matches": [
        "subgroup analysis",
        "stratification"
      ],
      "examples": [
        {
          "match": "Subgroup analysis",
          "context": "ice of chemotherapy. CAPTION: Subgroup analysis: efficacy analysis of patient"
        },
        {
          "match": "stratification",
          "context": "ab-paclitaxel8. Randomization stratification factors were HER2 IHC/ISH sta"
        },
        {
          "match": "stratification",
          "context": "ure that was corrected for misstratification. Sensitivity analyses perform"
        }
      ]
    },
    "variable_definitions": {
      "present": true,
      "count": 2,
      "unique_matches": [
        "primary endpoint"
      ],
      "examples": [
        {
          "match": "primary endpoint",
          "context": "nes2. The data cutoff for the primary endpoint of PFS by BICR in patients wi"
        },
        {
          "match": "primary endpoint",
          "context": "e for T-DXd versus TPC on its primary endpoint as well as key secondary endp"
        }
      ]
    },
    "analysis_principles": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "itt_details": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "software": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "error_measures": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "multiplicity_correction": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "normality_checks": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "p_values": {
      "present": true,
      "count": 2,
      "unique_matches": [
        "secondary endpoint"
      ],
      "examples": [
        {
          "match": "secondary endpoint",
          "context": "imary endpoint as well as key secondary endpoints (PFS by BICR in the overall"
        },
        {
          "match": "secondary endpoint",
          "context": "boundary for the primary and secondary endpoints was crossed during the prima"
        }
      ]
    },
    "confidence_intervals": {
      "present": true,
      "count": 5,
      "unique_matches": [
        "confidence interval",
        "95% ci"
      ],
      "examples": [
        {
          "match": "95% CI",
          "context": "ian follow-up of 32.0\u2009months (95% CI 31.0\u201332.8). The data cutoff d"
        },
        {
          "match": "95% CI",
          "context": "ed to calculate the two-sided 95% CIs for the medians of each trea"
        },
        {
          "match": "95% CI",
          "context": "to estimate hazard ratios and 95% CIs. The proportional hazard ass"
        }
      ]
    },
    "comparative_stats": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "non_parametric": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "advanced_modeling": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "assumption_checks": {
      "present": true,
      "count": 2,
      "unique_matches": [
        "proportional hazards"
      ],
      "examples": [
        {
          "match": "proportional hazards",
          "context": "eatment arm. A stratified Cox proportional hazards regression model was used to"
        },
        {
          "match": "proportional hazards",
          "context": "atio is from unstratified Cox proportional hazards model with treatment as the o"
        }
      ]
    },
    "survival_analysis": {
      "present": true,
      "count": 16,
      "unique_matches": [
        "overall survival",
        "os",
        "kaplan-meier",
        "hazard ratio"
      ],
      "examples": [
        {
          "match": "Kaplan-Meier",
          "context": "n time to first event is from Kaplan-Meier estimate. CI for median was c"
        },
        {
          "match": "hazard ratio",
          "context": "on model was used to estimate hazard ratios and 95% CIs. The proportiona"
        },
        {
          "match": "Hazard ratio",
          "context": "he Brookmeyer-Crowley method.bHazard ratio is from unstratified Cox prop"
        }
      ]
    },
    "regression_and_models": {
      "present": true,
      "count": 2,
      "unique_matches": [
        "cox proportional"
      ],
      "examples": [
        {
          "match": "Cox proportional",
          "context": "h treatment arm. A stratified Cox proportional hazards regression model was"
        },
        {
          "match": "Cox proportional",
          "context": "rd ratio is from unstratified Cox proportional hazards model with treatment"
        }
      ]
    },
    "reporting_guidelines": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "data_types": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "categorical"
      ],
      "examples": [
        {
          "match": "categorical",
          "context": "el with treatment as the only categorical variable in the model. Confid"
        }
      ]
    },
    "dependency": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "clustering": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "missing_data": {
      "present": true,
      "count": 4,
      "unique_matches": [
        "missing data",
        "imputation",
        "no imputation",
        "dropout"
      ],
      "examples": [
        {
          "match": "missing data",
          "context": "s (PFS and OS), patients with missing data were censored. Statistical an"
        },
        {
          "match": "dropout",
          "context": "was performed for missing or dropout data. In the time-to-event an"
        },
        {
          "match": "imputation",
          "context": "one dose of a trial drug. No imputation was performed for missing or"
        }
      ]
    },
    "effect_size": {
      "present": true,
      "count": 26,
      "unique_matches": [
        "hr",
        "hazard ratio"
      ],
      "examples": [
        {
          "match": "hazard ratio",
          "context": "on model was used to estimate hazard ratios and 95% CIs. The proportiona"
        },
        {
          "match": "Hazard ratio",
          "context": "he Brookmeyer-Crowley method.bHazard ratio is from unstratified Cox prop"
        },
        {
          "match": "HR",
          "context": "th hormone receptor-positive (HR+) metastatic breast cancer (m"
        }
      ]
    },
    "post_hoc": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "baseline_reporting": {
      "present": true,
      "count": 2,
      "unique_matches": [
        "baseline demographic"
      ],
      "examples": [
        {
          "match": "Baseline demographic",
          "context": "ked to this article. CAPTION: Baseline demographics and characteristics FOOTER:"
        },
        {
          "match": "baseline demographic",
          "context": "OOTER: Overall and HR+ cohort baseline demographics and characteristics data fro"
        }
      ]
    },
    "advanced_modeling_extra": {
      "present": true,
      "count": 3,
      "unique_matches": [
        "excluded",
        "categorized",
        "compliance"
      ],
      "examples": [
        {
          "match": "excluded",
          "context": "f radiotherapy. Patients were excluded from the trial if they had un"
        },
        {
          "match": "categorized",
          "context": "ession subgroups, tumors were categorized as ER >10% or ER-low-positive"
        },
        {
          "match": "compliance",
          "context": "gy report for HER2 testing in compliance with 2023 ASCO/CAP updates an"
        }
      ]
    },
    "systematic_review_metrics": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "diagnostic_metrics": {
      "present": true,
      "count": 1,
      "unique_matches": [
        "sensitivity"
      ],
      "examples": [
        {
          "match": "Sensitivity",
          "context": "rected for misstratification. Sensitivity analyses performed at the tim"
        }
      ]
    },
    "model_details": {
      "present": false,
      "count": 0,
      "unique_matches": [],
      "examples": []
    },
    "domain_indicators": {
      "present": true,
      "count": 4,
      "unique_matches": [
        "in vitro",
        "staining"
      ],
      "examples": [
        {
          "match": "staining",
          "context": "ER-low-positive (1%\u201310%) IHC staining as per ASCO/CAP guidelines2."
        },
        {
          "match": "In Vitro",
          "context": "S and ex-EU markets under the In Vitro Diagnostic Directive; as VENT"
        },
        {
          "match": "In Vitro",
          "context": "y in the CE markets under the In Vitro Diagnostic Directive; and as"
        }
      ]
    }
  }
}